C360 Spine Portfolio Unveiled – NuVasive Advises Launch Represents a Significant Opportunity for Growth As Cervical Spine Procedures Comprise An Approximately $2.6 Bil Segment of the Global Spine Market

November 30, 2020

NuVasive has expanded its product line with the introduction of a new C360 cervical spine portfolio. The company has also commercially launched its new anterior cervical plating (ACP) system, which is claimed to feature the thinnest plate on the market at 1.6mm.

NuVasive has designed a new ACP system to minimize common postoperative complications such as dysphagia, malalignment, and adjacent level ossification.

The system helps surgeons to customize treatment as per customer requirements compared to the traditional one-size-fits-all approach.

Features of new anterior cervical plating system

The new ACP system features three plate profiles, including a thin-plate for one and two levels, and offers optimized plate stiffness for each surgical level to support construct stability.

NuVasive’s system offers a range of implant length options to match different patient anatomies and maximize the distance from the adjacent levels.

In addition, the system consists of a range of advanced screw offerings with integrated locking covers to facilitate better screw placement and locking accuracy.

The C360 portfolio also includes the Reline Cervical posterior fixation system, which is expected to be commercialized in 2021.

NuVasive executive vice president Massimo Calafiore said: “As the leader in spine technology innovation, NuVasive saw an opportunity to procedurally integrate technology to support the cervical spine—as it did in the lateral market with X360—to optimize the surgeon experience and advance care in the operating room.

“The launch of C360 is key to our long-term strategy and represents a significant opportunity for growth, as cervical spine procedures comprise an approximately $2.6 billion segment of the global spine market.”

NuVasive offers procedural solutions, including access, implants and fixation systems, biologics, software for surgical planning, and navigation and imaging solutions.

In November, NuVasive expanded its Porous PEEK portfolio with the commercial introduction of a new Cohere extreme lateral interbody fusion (XLIF) system.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”